BG Medicine is a diagnostics company focused on the development and commercialization of novel cardiovascular tests. The company has two products: the Galectin-3 test for use in patients with chronic heart failure and the CardioSCORE test for the risk prediction of major cardiovascular events.
The company today announced the publication of two studies (in the United States and Europe) demonstrating the clinical utility of repeated galectin-3 testing as a useful tool in the assessment of patients with heart failure. The studies, which involved more than 3,300 subjects, demonstrated clearly that periodic evaluation of galectin-3 levels helped doctors identify those patients at greater clinical risk of a cardiac event.
Galectin-3 is a unique carbohydrate-binding lectin, or protein. It has been implicated in a variety of biological processes involved in the development and progression of heart failure. Galectin-3 is also believed to be a primary factor in abnormal thickening and stiffening of the heart muscle and in changes in the heart structure.
The company’s president and CEO, Eric Bouvier, commented on the publication of the studies, “We are very encouraged by these published results, which add to the growing body of evidence supporting thr repeated use of galectin-3 testing as an ongoing monitoring tool in the care of patients with heart failure.”
For additional information, visit www.bg-medicine.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
